ArticleFrontiers in immunology2026
Thymic stromal lymphopoietin promotes abdominal aortic aneurysm formation by regulating macrophage polarization.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The inflammatory cytokine thymic stromal lymphopoietin (TSLP) has pleiotropic roles in immune response and tissue homeostasis, yet its function in abdominal aortic aneurysm (AAA) remains entirely unexplored. Methods: We integrated clinical epidemiology, Results: AAA patients showed a markedly elevated serum TSLP. In murine models, TSLP was increased in the aortic tissues, primarily derived from fibroblasts. Genetic ablation of Tslpr and pharmacological neutralization of TSLP attenuated the severity of AAA, while exogenous TSLP exacerbated the disease. CyTOF analysis revealed that TSLP signaling skewed the aortic macrophage balance toward the pro-inflammatory M1 phenotype rather than the anti-inflammatory M2 phenotype. Conclusions: Our integrated multi-level analysis has identified TSLP as a novel pathogenic driver of AAA, which promotes disease progression by reprogramming macrophage polarization. These findings nominate TSLP signaling as a mechanistically grounded and therapeutically promising target for AAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.